New York Senate Bill S09852

New York 2025-2026 Regular Session

• Introduced: 4/8/26
• Refer: 4/8/26

Caption

Provides that when a drug is designated or rescheduled by the federal government, it shall be deemed scheduled under NYS law automatically, without further action by the commissioner.

Summary

This bill amends New York’s Public Health Law provisions governing controlled substances schedules. It changes the state’s process for certain drugs that are already listed in Schedule I under New York law but are later approved by the federal Food and Drug Administration and rescheduled by the federal Drug Enforcement Administration. For those compounds, mixtures, or preparations, the bill provides that they will be automatically deemed scheduled under New York law in the same schedule assigned under federal law, effective on the date of the federal action, without requiring any additional action by the state commissioner. The bill also revises the existing reclassification language in section 3307 of the Public Health Law to clarify that the commissioner’s authority to reclassify or exempt a substance does not apply to the newly added automatic-scheduling category. In practical terms, the measure is designed to align state controlled-substance scheduling more quickly with federal rescheduling decisions, while preserving the state’s broader controlled substances framework.

Impact

The bill would amend sections 3306 and 3307 of the Public Health Law, affecting how New York schedules controlled substances and how quickly state law tracks federal drug scheduling changes. It would reduce the need for separate state regulatory action when a federally approved substance is moved out of Schedule I, and it would create a self-executing rule for those substances under state law. The main parties affected would be the Department of Health, the commissioner’s office, regulated manufacturers and prescribers, pharmacies, and law enforcement entities that rely on the state schedules.

Sentiment

No committee transcript or vote record is available, so there is no documented debate or recorded floor sentiment to assess. Based on the bill text and caption, the measure appears to be a technical, administrative alignment bill intended to streamline scheduling and reduce delay between federal and state action. The available context suggests a neutral-to-supportive policy posture focused on efficiency and conformity with federal drug control decisions.

Contention

The principal policy issue is the reduction of state discretion: the bill would make certain federally rescheduled substances automatically controlled under New York law without further commissioner action. Supporters would likely view this as a modernization and administrative efficiency measure, while any critics might be concerned about limiting state review or accelerating the state’s adoption of federal scheduling decisions. No specific opposition, amendments, or stakeholder objections are documented in the provided materials.